225 related articles for article (PubMed ID: 24825850)
1. VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.
Solomon JD; Heitzer MD; Liu TT; Beumer JH; Parise RA; Normolle DP; Leach DA; Buchanan G; DeFranco DB
Mol Cancer Res; 2014 Aug; 12(8):1166-80. PubMed ID: 24825850
[TBL] [Abstract][Full Text] [Related]
2. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
Li X; Martinez-Ferrer M; Botta V; Uwamariya C; Banerjee J; Bhowmick NA
Oncogene; 2011 Jan; 30(2):167-77. PubMed ID: 20818421
[TBL] [Abstract][Full Text] [Related]
3. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
[TBL] [Abstract][Full Text] [Related]
4. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL
Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821
[TBL] [Abstract][Full Text] [Related]
5. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and VDR polymorphism.
Maj E; Trynda J; Maj B; Gębura K; Bogunia-Kubik K; Chodyński M; Kutner A; Wietrzyk J
J Steroid Biochem Mol Biol; 2019 Oct; 193():105431. PubMed ID: 31326626
[TBL] [Abstract][Full Text] [Related]
6. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells.
Yang L; Yang J; Venkateswarlu S; Ko T; Brattain MG
J Cell Physiol; 2001 Sep; 188(3):383-93. PubMed ID: 11473365
[TBL] [Abstract][Full Text] [Related]
7. Without 1α-hydroxylation, the gene expression profile of 25(OH)D
Susa T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
Sci Rep; 2018 Jun; 8(1):9024. PubMed ID: 29899561
[TBL] [Abstract][Full Text] [Related]
8. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells.
Heitzer MD; DeFranco DB
Cancer Res; 2006 Jul; 66(14):7326-33. PubMed ID: 16849583
[TBL] [Abstract][Full Text] [Related]
9. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
10. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.
Giangreco AA; Dambal S; Wagner D; Van der Kwast T; Vieth R; Prins GS; Nonn L
J Steroid Biochem Mol Biol; 2015 Apr; 148():156-65. PubMed ID: 25305352
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
12. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
[TBL] [Abstract][Full Text] [Related]
13. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
García-Quiroz J; García-Becerra R; Barrera D; Santos N; Avila E; Ordaz-Rosado D; Rivas-Suárez M; Halhali A; Rodríguez P; Gamboa-Domínguez A; Medina-Franco H; Camacho J; Larrea F; Díaz L
PLoS One; 2012; 7(9):e45063. PubMed ID: 22984610
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment.
Hidalgo AA; Montecinos VP; Paredes R; Godoy AS; McNerney EM; Tovar H; Pantoja D; Johnson C; Trump D; Onate SA
Biochem Biophys Res Commun; 2011 Aug; 412(1):13-9. PubMed ID: 21763285
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Doherty D; Dvorkin SA; Rodriguez EP; Thompson PD
Prostate; 2014 Feb; 74(3):273-85. PubMed ID: 24242708
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and Action of 25-Hydroxy-19-nor-Vitamin D₃ in Human Prostate Cells.
Munetsuna E; Kittaka A; Chen TC; Sakaki T
Vitam Horm; 2016; 100():357-77. PubMed ID: 26827959
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D Signaling Modulators in Cancer Therapy.
Luo W; Johnson CS; Trump DL
Vitam Horm; 2016; 100():433-72. PubMed ID: 26827962
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.
Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M
J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
